Platelet thrombin receptor antagonism with vorapaxar: Pharmacology and clinical trial development

Future Cardiology

Volumn 11, Issue 5, 2015, Pages 547-564

  Franchi, Francesco ^a   Rollini, Fabiana ^a   Park, Yongwhi ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

antiplatelet therapy; platelet aggregation; protease activated receptor 1; thrombin; vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; ATOPAXAR; CLOPIDOGREL; THROMBIN RECEPTOR; VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; ISCHEMIA; METABOLISM; PROCEDURES; THROMBOCYTE;

ATHEROSCLEROSIS; BLOOD PLATELETS; CLINICAL TRIALS AS TOPIC; HUMANS; ISCHEMIA; LACTONES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTORS, THROMBIN; SECONDARY PREVENTION;

EID: 84945543489     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.50     Document Type: Article

References (87)

1. Davì G, Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357(24), 2482-2494 (2007).
2. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ. J. 74(4), 597-607 (2010).
3. Angiolillo DJ, Ferreiro JL. Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. Am. J. Cardiovasc. Drugs 13(4), 233-250 (2013).
4. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12(1), 30-47 (2015).
5. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur. Heart J. 31(1), 17-28 (2010).
6. Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. Drugs 70 (14), 1771-1783 (2010).
7. Rollini F, Tello-Montoliu A, Angiolillo DJ. Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. Future Cardiol. 8(4), 503-511 (2012).
8. Cho JR, Rollini F, Franchi F, Ferrante E, Angiolillo DJ. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vasc. Health Risk Manag. 10, 177-188 (2014).
9. Patrono C, García Rodríguez LA, Landolf R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353(22), 2373-2383 (2005).
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
11. Sherwood M W, Wiviott SD, Peng SA et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J. Am. Heart Assoc. 3(2), e000849 (2014).
12. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001).
13. Steinhubl SR, Berger PB, Mann JT 3rd. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411-2420 (2002).
14. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497), 1607-1621 (2005).
15. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505-1516 (2007).
16. Tantry US, Bonello L, Aradi D et al. Consensus and update on the defnition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62(24), 2261-2273 (2013).
17. Stone GW, Witzenbichler B, Weisz G et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382 (9892), 614-623 (2013).
18. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007).
19. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009).
20. Brummel-Ziedins K, Undas A, Orfeo T et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J. Thromb. Haemost. 6(1), 104-110 (2008).
21. Oldgren J, Wallentin L, Alexander JH et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur. Heart J. 34(22), 1670-1680 (2013).
22. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366(1), 9-19 (2012).
23. Coughlin SR. Pro tease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3(8), 1800-1814 (2005).
24. Brass LF. Thrombin and platelet activation. Chest 124(Suppl. 3), 18S-25S (2003).
25. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 84(2), 579-621 (2004).
26. Shah R. Protease-activated receptors in cardiovascular health and diseases. Am. Heart J. 157(2), 253-262 (2009).
27. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 103(6), 879-887 (1999).
28. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc. Natl. Acad. Sci. USA 96(20), 11189-11193 (1999).
29. Kim S, Foster C, Lecchi A et al. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 99(10), 3629-3636 (2002).
30. Nylander S, Mattsson C, Ramström S, Lindahl TL. Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP-and thrombin-induced human platelet activation. Br. J. Pharmacol. 142(8), 1325-1331 (2004).
31. Kato Y, Kita Y, Hirasawa-Taniyama Y et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur. J. Pharmacol. 473(2-3), 163-169 (2003).
32. Doller D, Chackalamannil S, Czarniecki M, McQuade R, Ruperto V. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg. Med. Chem. Lett. 9(6), 901-906 (1999).
33. Chackalamannil S, Wang Y, Greenlee WJ et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J. Med. Chem. 51(11), 3061-3064 (2008).
34. Pharmacology of a selective, orally active thrombin receptor antagonist, SCH 530348. Report no. 46293. Schering-Plough Research Institute. Kenilworth NJ, USA (2004).
35. Ghosal A, Lu X, Penner N, Gao L et al. Identifcation of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab. Dispos. 39(1), 30-38 (2011).
36. Kosoglou T, Statkevich P, Kumar B et al. The effect of multiple doses of ketoconazole or rifampin on the single-and multiple-dose pharmacokinetics of vorapaxar. J. Clin. Pharmacol. 53(5), 540-549 (2013).
37. Kosoglou T, Kraft WK, Kumar B et al. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur. J. Clin. Pharmacol. 68(7), 1049-1056 (2012).
38. Statkevich P, Kosoglou T, Preston RA et al. Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. Eur. J. Clin. Pharmacol. 68(11), 1501-8 (2012).
39. Reyderman L, Kosoglu T, Tseng J et al. The effect of food and antiacid on pharmacokinetics (PK) of SCH 530348 in healthy subjects. Clin. Pharmacol. Ther. 85(Suppl. 1), S21 (2009).
40. Kosoglou T, Reyderman L, Tiessen RG et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur. J. Clin. Pharmacol. 68(3), 249-258 (2012).
41. Kosoglou T, Reyderman L, Kasserra C et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clin. Pharmacol. Ther. 83(Suppl. 1), S55 (2008).
42. Kosoglou T, Reyderman L, Kasserra C et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur. J. Clin. Pharmacol. 68(3), 291-300 (2012).
43. Becker RC, Moliterno DJ, Jennings LK et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled Phase II study. Lancet 373(9667), 919-928 (2009).
44. Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. Safety and exploratory effcacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J. Atheroscler. Thromb. 17(2), 156-164 (2010).
45. Tricoci P, Huang Z, Held C et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366(1), 20-33 (2012).
46. Morrow DA, Braunwald E, Bonaca MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366(15), 1404-1413 (2012).
47. Storey RF, Kotha J, Smyth SS et al. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb. Haemost. 111(5), 883-891 (2014).
48. Leonardi S, Tricoci P, White HD et al. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial. Eur. Heart J. 34(23), 1723-1731 (2013).
49. White HD, Huang Z, Tricoci P et al. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. J. Am. Heart Assoc. 3(4), e001032 (2014).
50. Valgimigli M, Tricoci P, Huang Z et al. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am. J. Cardiol. 114(5), 665-673 (2014).
51. Tricoci P, Lokhnygina Y, Huang Z et al. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am. Heart J. 168(6), 869-877 (2014).
52. Mahaffey KW, Huang Z, Wallentin L et al. Association of aspirin dose and vorapaxar safety and effcacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am. J. Cardiol. 113(6), 936-944 (2014).
53. Cornel JH, Tricoci P, Lokhnygina Y et al. Glycoprotein IIb/IIIa receptor inhibitors in combination with vorapaxar, a platelet thrombin-receptor antagonist, among patients with non-ST-segment elevation acute coronary syndromes (from the TRACER trial). Am. J. Cardiol. 115(10), 1325-1332 (2015).
54. Held C, Tricoci P, Huang Z et al. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Eur. Heart J. Acute Cardiovasc. Care 3(3), 246-256 (2014).
55. Whellan DJ, Tricoci P, Chen E et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (thrombin receptor antagonist for clinical event reduction in acute coronary syndrome). J. Am. Coll. Cardiol. 63(11), 1048-1057 (2014).
56. Tricoci P, Huang Z, van de Werf F et al. Net clinical beneft of vorapaxar in NSTE ACS: role of Ischemic and bleeding risk stratifcation. Circulation 126, A19049 (2012).
57. Jones WS, Tricoci P, Huang Z et al. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER). Am. Heart J. 168(4), 588-596 (2014).
58. Bonaca MP, Scirica BM, Braunwald E et al. Effcacy of vorapaxar is not modifed by thienopyridine therapy: results from TRA 2P-TIMI 50 trial. Circulation 126, A18595 (2012).
59. Scirica BM, Bonaca MP, Braunwald E et al. Vorapaxar for secondary prevention after myocardial infarction according to aspirin dose-insights from the TRA 2P-TIMI 50 trial. Circulation 126, A14508 (2012).
60. Morrow DA, Alberts MJ, Mohr JP et al. Effcacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 44(3), 691-698 (2013).
61. Scirica BM, Bonaca MP, Braunwald E et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecifed subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 380(9850), 1317-1324 (2013).
62. Bonaca MP, Scirica BM, Creager MA et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 127(14), 1522-1529 (2013).
63. Magnani G, Bonaca MP, Braunwald E et al. Effcacy and safety of vorapaxar as approved for clinical use in the United States. J. Am. Heart. Assoc. 4(3), e001505 (2015).
64. Cavender MA, Scirica BM, Bonaca MP et al. Vorapaxar in patients with diabetes and prior MI: fndings from the TRA 2°P-TIMI 50 trial. Circulation doi:10.1161/CIRCULATIONAHA.114.013774 (2015) (Epub ahead of print).
65. SPS3 Investigators. Benavente OR, Hart RG, McClure LA et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N. Engl. J. Med. 367(9), 817-825 (2012).
66. Bonaca MP, Scirica BM, Braunwald E et al. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J. Am. Coll. Cardiol. 64(22), 2318-2326 (2014).
67. Diener HC, Weber R. Clopidogrel added to aspirin adds no beneft but bleeding risk in patients with recent lacunar stroke. Stroke 44(3), 861-863 (2013).
68. Wang Y, Wang Y, Zhao X et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N. Engl. J. Med. 369(1), 11-19 (2013).
69. Bonaca MP, Scirica BM, Braunwald E et al. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. J. Am. Coll. Cardiol. 64(22), 2309-2317 (2014).
70. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ. Res. 88(10), 987-997 (2001).
71. Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 298 (7), 765-775 (2007).
72. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123(7), 798-813 (2011).
73. FDA. Vorapaxar prescribing information. www.fda.gov/drugs/informationondrugs/ucm423935.htm
74. Bonaca MP, Scirica BM, Braunwald E et al. Outcomes in stable patients with prior atherothrombosis receiving vorapaxar who present with a new acute coronary syndrome: insights from the TRA2P-TIMI 50 trial. Circulation 130, A20483 (2014).
75. van Diepen S, Tricoci P, Podder M et al. Effcacy and safety of vorapaxar in non-ST-segment elevation acute coronary syndrome patients undergoing non-cardiac s urger y. Circulation 130, A12191 (2014).
76. EMA. Vorapaxar prescribing information. www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/002814/human-med-001839. jsp&mid=WC0b01ac058001d124
77. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 130(25), e344-e426 (2014).
78. Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35(37), 2541-2619 (2014).
79. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49 (19), 1982-1988 (2007).
80. Wiviott SD, White HD, Ohman EM et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecifed analysis of the TRILOGY ACS trial. Lancet 382(9892), 605-613 (2013).
81. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med. 371(23), 2155-2166 (2014).
82. Yeh RW, Kereiakes DJ, Steg PG et al. Benefts and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J. Am. Coll. Cardiol. 65(20), 2211-2221 (2015).
83. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372(19), 1791-1800 (2015).
84. ClinicalTrials Database: NCT01830543. https://clinicaltrials.gov/ct2/show/NCT01830543
85. ClinicalTrials Database: NCT02164864. https://clinicaltrials.gov/ct2/show/NCT02164864?term=NCT02164864&rank=1
86. ClinicalTrials Database: NCT01813435. https://clinicaltrials.gov/ct2/show/NCT01813435?term=NCT01813435&rank=1
87. ClinicalTrials Database: NCT02270242. https://clinicaltrials.gov/ct2/show/NCT02270242?term=NCT02270242&rank=1